All the Active Ingredient Drugs
Anti-CD33. Gemtuzumab Ozogamicin 5 mg. VIAL (Pwdr. for concent. for sol. for infus.): 1×4.5 mg. Dosage must be adjust. individual.
Newly-Diagnosed CD33-positive Acute Myeloid Leukemia (AML): MYLOTARG is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults.
Relapsed or Refractory CD33-positive AML: MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older.